Medacta Group Sa · SIX:MOVE

Medacta Group Sa — H1 2021 Earnings Presentation

10 slides from Medacta Group Sa's earnings presentation, Jul 20, 2021

  1. Slide 1: 1H 2021 Preliminary Unaudited Top-Line Figures

    1H 2021 Preliminary Unaudited Top-Line Figures 20 July 2021

  2. Slide 2: Disclaimer

    Disclaimer This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on ou

  3. Slide 3: Presenters: Francesco Siccardi and Corrado Farsetta

    FRANCESCO SICCARDI CORRADO FARSETTA Chief Executive Officer Chief Financial Officer 1H 2021 Preliminary Unaudited Top-Line Figures

  4. Slide 4: 1H 2021 Highlights

    1H 2021 Highlights  1H 2021 revenue increased to Euro 177.5 million, or 35.4% at constant currency (31.7% reported) vs 1H 2020  The growth was driven by significant carry-over and customer acquisition, in addition to faster-than-expected normalization of surgery activities  Positive contributions

  5. Slide 5: 1H 2021 Revenue Bridge by Product Line

    1H 2021 Revenue1 Bridge by Product Line (€m) 30.7% 38.4% 56.8% 39.5% 35.4% 31.7% 16.6; 9% (€m) 9.1; 5% 88.4; 63.4; 50% 36% 2 Hip Knee Extremities Spine  The good momentum of Hip was generated by the acquisition of new customers through the AMIS strategy supported by the roll-out of new products  T

  6. Slide 6: 1H 2021 Revenue Bridge by Geographic Area

    1H 2021 Revenue1 Bridge by Geographic Area (€m) 29.4% 44.3% 33.6% 49.4% 35.4% 31.7% 5.7; 3% (€m) 43.0; 24% 76.2; 43% 52.5; 30% Europe NA APAC ROW  In Europe, France, Italy and Belgium, the countries most affected by Covid-19 in 1H 2020, recorded the strongest growth, followed by the “DACH” countrie

  7. Slide 7: Deployment of the NextAR AR Surgical Platform

    Deployment of the NextAR™ AR Surgical Platform  In June 2021, the first surgeries based on our NextAR Augmented Reality (AR) Surgical Platform were performed in Europe, following the CE-marking of the Knee, Shoulder and Spine Applications  Also, in May 2021, the NextAR Shoulder Application receive

  8. Slide 8: 2021 Outlook

    2021 Outlook  Our strong customer acquisition, together with the progressive normalization of surgery activities benefiting from vaccinations, resulted in a stronger than expected sales performance in the first semester 2021  The second semester 2021 growth is expected to normalize as the second s

  9. Slide 9: Q&A

    Q&A FY 2020 Financial Results

  10. Slide 10: Adedacta

    Adedacta International

Medacta Group — H1 2021 Earnings Presentation on 6ix